DIAGNOS (CVE:ADK) Sets New 12-Month High – Still a Buy?

DIAGNOS Inc. (CVE:ADK) shares hit a new 52-week high during trading on Monday . The stock traded as high as C$0.53 and last traded at C$0.48, with a volume of 253755 shares. The stock had previously closed at C$0.45.

DIAGNOS Trading Up 8.9%

The company has a debt-to-equity ratio of 204.05, a current ratio of 1.49 and a quick ratio of 0.68. The company has a fifty day simple moving average of C$0.35 and a two-hundred day simple moving average of C$0.28. The company has a market capitalization of C$59.31 million, a P/E ratio of -12.25 and a beta of 0.50.

Insider Transactions at DIAGNOS

In other news, Director Robert Dunn bought 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were purchased at an average price of C$0.30 per share, for a total transaction of C$60,000.00. Following the acquisition, the director directly owned 2,117,778 shares of the company’s stock, valued at C$635,333.40. The trade was a 10.43% increase in their position. In the last quarter, insiders have acquired 433,571 shares of company stock valued at $146,400. Company insiders own 16.81% of the company’s stock.

About DIAGNOS

DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.